This page is a permanent link to the reply below and its nested replies. See all post replies »
ElwoodBlues · M
@Patriot96 claims
Here's what the experts said, with links.
"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine"
https://www.nejm.org/doi/full/10.1056/nejmoa2035389
Conclusions
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
https://www.nejm.org/doi/full/10.1056/nejmoa2034577
Results
A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. ...
Conclusions
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
To paraphrase St Ronald of Reagan:
The trouble with our conservative friends is not that they're ignorant; it's just that they know so much that isn't so.
experts told us we would not contract covid if we were vaccinated
BULLL SHITTTHere's what the experts said, with links.
"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine"
https://www.nejm.org/doi/full/10.1056/nejmoa2035389
Conclusions
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
https://www.nejm.org/doi/full/10.1056/nejmoa2034577
Results
A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. ...
Conclusions
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
To paraphrase St Ronald of Reagan:
The trouble with our conservative friends is not that they're ignorant; it's just that they know so much that isn't so.